Oppenheimer Reiterates Outperform Rating on Coherus Biosciences (CHRS): "buying opportunity ahead of key catalysts"
Tweet Send to a Friend
Oppenheimer analyst Jay Olson reiterated an Outperform rating and $10.00 price target on Coherus Biosciences (NASDAQ: CHRS)The analyst commented, "CHRS ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
